BIOVENTRIX, INC.
StreetZero Signal 72
About BIOVENTRIX, INC.
BioVentrix, Inc. is a privately held medical device company focused on the development of less invasive therapies to treat the failing left ventricle (LV), the most common cause of heart failure. BioVentrix technologies aim to improve cardiac function by directly addressing LV dilation. The Company is preparing to submit the PMA application to the FDA later this year. The financing will support completion of the BioVentrix Premarket Approval (PMA) submission for its Revivent TC System.
LATEST FUNDINGPrivate Placement
$1.2M
Announced 2026-10-08
IN THE NEWS
- 🔗 BioVentrix® Closes $48.5 Million Series A Financing
- 🔗 BioVentrix® Closes $48.5 Million Series A Financing - BioVentrix
- 🔗 Bioventrix - 2026 Company Profile, Team, Funding & Competitors - Tracxn
- 🔗 BioVentrix: Funding, Team & Investors | Startup Intros
- 🔗 BioVentrix Stock Price, Funding, Valuation, Revenue & Financial Statements
EMPLOYEES—
FOUNDED2003
HQMansfield, MA, United States
Industry
Biotechnology
Tags
Medical DeviceBiotechnologyHeart FailurePMA
Investors
Key highlights
- Closed $48.5M Series A in 2023 to fund PMA submission and launch prep.
- Developing Revivent TC System for less-invasive LV reconstruction.
- HQ located at 120 Forbes Boulevard, Mansfield, MA.
- Raised more than $189M across multiple rounds since 2004.
Ask StreetZero about BIOVENTRIX, INC.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account